Biosimilars: New guns for the treatment of rheumatologic patients?

  • Daniela Marotto Rheumatology Unit, P. Dettori Hospital, Tempio Pausania (SS), Italy.
  • Angela Ceribelli Rheumatology Unit, ASST Fatebenefratelli-Sacco, Milan, Italy.
  • Piercarlo Sarzi Puttini | Rheumatology Unit, ASST Fatebenefratelli-Sacco, Milan; University of Milan, Italy, Italy.


The advent of biological therapies in 2000s has represented a real revolution in the treatment of patients affected by rheumatic diseases, but biosimilars represent nowadays a further revolution both from an economic point of view and for the accessibility to treatment for rheumatic patients. The main scientific rheumatologic societies have clearly expressed themselves on the biosimilars topic, by highlighting how they represent a great opportunity to contain costs and treat more patients, and these advantages should be accepted by rheumatologists. The use of biosimilars in different European countries varies widely; in fact, in some of them their use is mandatory (at least in naïve patients), while in other countries it is only recommended. The knowledge and consequently the acceptance of biosimilars are different among patients, and this also depends on the correct medical information on this topic. As more and more biosimilars receive regulatory approval and reach the market, it is essential for healthcare professionals to have the right knowledge about them, so that they are properly transferred to their patients. Biosimilars are not identical to the reference product, and clinicians are particularly interested in the safety and effectiveness of switching from the biooriginator to the bio-similar in experienced patients. We will develop these aspects on biosimilars in the present manuscript, for an update on current guidelines in their use in rheumatic patients.


Download data is not yet available.
Biological therapies, biosimilars, switch, swap, interchangeability, guidelines, recommendations.
Abstract views: 105

PDF: 51
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Marotto, D., Ceribelli, A., & Sarzi Puttini, P. (2019). Biosimilars: New guns for the treatment of rheumatologic patients?. Beyond Rheumatology, 1(1), 15-21.

Most read articles by the same author(s)